A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms NIMBLe
- 28 Feb 2022 Status changed from active, no longer recruiting to discontinued.
- 25 Jan 2022 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.
- 08 Nov 2021 Planned End Date changed from 30 Sep 2021 to 31 Dec 2021.